The case for wider use of recombinant factor VIII concentrates
| Autor: | Cedric Hermans, Hans-Hermann Brackmann, G. Auerswald, Piercarla Schinco |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Hemophilia A Recombinant factor viii Drug Administration Schedule Plasma Immune Tolerance medicine Humans Intensive care medicine Clotting factor Clinical Trials as Topic Cross Infection Factor VIII business.industry Disease Management Hematology Surgery Oncology Virus Diseases Practice Guidelines as Topic Plasma chemistry Blood Component Removal Infectious risk Patient representatives Drug Contamination business |
| Zdroj: | Critical Reviews in Oncology/Hematology. 83:11-20 |
| ISSN: | 1040-8428 |
| DOI: | 10.1016/j.critrevonc.2011.08.001 |
| Popis: | The introduction of clotting factor concentrates led to major advances in hemophilia care. Rather than simply providing an alternative to plasma-derived concentrates, the introduction in the 1990s of recombinant concentrates added value to replacement therapy particularly with respect to prophylaxis and immune-tolerance induction. While the safety of plasma-derived concentrates has improved considerably, these concentrates may still pose an infectious risk through as-yet unknown pathogens and poor impurity constituent characterization. Recombinant concentrates are increasingly used because of their benefits in pathogen safety, convenience and the potential for unfettered supply. Yet worldwide they remain accessible only to a limited number of patients due to fear of the potential for inhibitor development, overestimation of their costs and underestimation of their benefits. This article reviews the characteristics and properties of recombinant FVIII concentrates to help physicians and patient representatives promote the right of access of patients to the safest products. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect